Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Small molecules

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    32 result(s) found for: Small molecules. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2022-004136-26 Sponsor Protocol Number: S67063 Start Date*: 2023-06-28
    Sponsor Name:KU Leuven/UZ Leuven
    Full Title: Pharmacokinetics of edoxaban in geriatric patients with atrial fibrillation
    Medical condition: Stroke prevention in atrial fibrillation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10016566 Fibrillation atrial LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005393-73 Sponsor Protocol Number: ERLOPET_01 Start Date*: 2007-09-14
    Sponsor Name:University Cologne
    Full Title: A Phase II Clinical Trial to Evaluate the Accuracy of FDG-/FLT- PET for Early Prediction of Non-Progression in Patients with Advanced Non Small Cell Lung Cancer (NSCLC) treated with Erlotinib and t...
    Medical condition: The trial will be conducted in patients with non-small cell lung cancer in stage IIIb - IV
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003218-42 Sponsor Protocol Number: RC18_0287 Start Date*: 2019-01-16
    Sponsor Name:CHU de Nantes
    Full Title: Phase 2 study evaluating MEchanisms of resistance on tumor tissue and Liquid biopsy in patients with EGFR mutated nonpretreated advanced Lung cancer Receiving OSimErtinib until and beyond radiologi...
    Medical condition: Locally advanced or metastatic Non-small-cell lung carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020729-42 Sponsor Protocol Number: LDOS002 Start Date*: Information not available in EudraCT
    Sponsor Name:Helix BioPharma Corp
    Full Title: A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47 as a Monotherapy in Non-Squamous Non-Small Cell Lung Cancer Patients
    Medical condition: Inoperable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-002328-18 Sponsor Protocol Number: BP40657 Start Date*: 2018-12-19
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A RANDOMIZED, MULTICENTER, PHASE Ib/III STUDY TO INVESTIGATE THE PHARMACOKINETICS, EFFICACY, AND SAFETY OF ATEZOLIZUMAB SUBCUTANEOUS COMPARED WITH ATEZOLIZUMAB INTRAVENOUS IN PATIENTS WITH PREVIOUS...
    Medical condition: Non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059514 Small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) PL (Completed) HU (Completed) GR (Completed) BG (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002382-19 Sponsor Protocol Number: PDC-LUNG-101 Start Date*: 2019-06-13
    Sponsor Name:PDC*line Pharma SAS
    Full Title: An open-label, dose-escalation, phase I/II study to assess the safety, the tolerability, the immunogenicity and the preliminary clinical activity of the therapeutic cancer vaccine, PDC*lung01, asso...
    Medical condition: Non-small-cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003593-17 Sponsor Protocol Number: BNT411-01 Start Date*: 2021-02-18
    Sponsor Name:BioNTech SE
    Full Title: Phase 1/2a, first-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BNT411 as a monotherapy in p...
    Medical condition: Chemotherapy-naïve extensive-stage small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2004-005096-42 Sponsor Protocol Number: BO18279 Start Date*: 2005-06-24
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A phase II marker identification trial for Tarceva in second line NSCLC patients
    Medical condition: Advanced (stage IIIb and IV) non small cell lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) EE (Completed) DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-003334-25 Sponsor Protocol Number: Uni-Koeln-2785 Start Date*: 2017-01-26
    Sponsor Name:University of Cologne
    Full Title: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in relapsed lung cancer and to evaluate biomarkers predictive for response to immune checkpoint inhibition
    Medical condition: Patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) and patients with Small cell lung cancer (SCLC) after failure of platinum-based first-line therapy.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041070 Small cell lung cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059514 Small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002622-87 Sponsor Protocol Number: BeliVeR Start Date*: 2021-10-27
    Sponsor Name:University Hospital Tuebingen
    Full Title: A phase II trial of belimumab in combination with rituximab/venetoclax in patients with refractory or relapsed chronic lymphocytic leukemia
    Medical condition: Refractory or relapsed chronic lymphocytic leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009310 CLL LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-002537-41 Sponsor Protocol Number: 20170104 Start Date*: 2022-01-06
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects with Moderately to Sev...
    Medical condition: Moderate to Severe Active Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) FI (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) RO (Trial now transitioned) SK (Trial now transitioned) LV (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-000568-32 Sponsor Protocol Number: CLLTX1 Start Date*: 2017-11-07
    Sponsor Name:Universität Köln
    Full Title: Obinutuzumab containing conditioning regimen for CLL patients and patients with Richter`s transformation requiring an allogeneic stem cell transplantation
    Medical condition: Patients with poor risk CLL and Richter`s transformation requiring an allogeneic stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058728 Richter's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-001555-19 Sponsor Protocol Number: HE 2D07 Start Date*: 2008-02-26
    Sponsor Name:Hellenic Cooperative Oncology Group
    Full Title: DOCETAXEL COMBINED WITH PULSATILE ERLOTINIB (TARCEVA) IN PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER (NSCLC)
    Medical condition: Metastatic (stage IV) non-small cell lung cancer (NSCLC) who have not previously been treated with anticancer drugs
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-004566-13 Sponsor Protocol Number: EMR62206-017 Start Date*: 2007-03-06
    Sponsor Name:MERCK KGaA
    Full Title: An open-label, randomised, phase II study in subjects with extensive disease, small cell lung cancer (ED-SCLC) after an initial response (complete response or partial response) to platinum-based th...
    Medical condition: extensive disease, small cell lung cancer (ED-SCLC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041071 Small cell lung cancer stage unspecified PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-012714-49 Sponsor Protocol Number: CHUBX 2009/04 Start Date*: 2009-11-24
    Sponsor Name:CHU de Bordeaux
    Full Title: Pilot study of Lapatinib (Tyverb®) in néoadjuvant treatment for patients with locally bladder carcinoma before cystectomy
    Medical condition: Bladder carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005015 Bladder carcinoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002328-35 Sponsor Protocol Number: CANTABRICO Start Date*: 2020-11-11
    Sponsor Name:AstraZeneca Farmacéutica Spain, S.A
    Full Title: A Phase IIIB, Single Arm Study, of Durvalumab in Combination with Platinum-Etoposide for Untreated Patients with Extensive-Stage Small Cell Lung Cancer reflecting Real World Clinical Practice in Sp...
    Medical condition: Extensive-Stage Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2014-002714-23 Sponsor Protocol Number: LLC1114 Start Date*: 2015-01-07
    Sponsor Name:Fondazione G.I.M.EM.A. Onlus Gruppo Italiano Malattie Ematologiche dell'Adulto
    Full Title: A phase 2 multicenter study to assess the activity and the safety of front-line Ibrutinib plus Rituximab (IR) in unfit patients with Chronic Lymphocytic Leukemia (CLL).
    Medical condition: Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10024340 Leukemia lymphocytic chronic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012964-14 Sponsor Protocol Number: XL184-203 Start Date*: 2010-03-10
    Sponsor Name:Exelixis Inc
    Full Title: A randomized discontinuation study of XL184 in subjects with advanced solid tumors
    Medical condition: To evaluate the efficacy of XL184 in subjects with one of the following advanced solid tumors: a. Breast Cancer b. Gastric and Gastroesophageal Junction Cancer c. Hepatocellular Carcinoma (HCC) ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-002139-41 Sponsor Protocol Number: R1979-ONC-1625 Start Date*: 2019-09-11
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an anti CD20 x anti-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Follicular Lymphoma
    Medical condition: Follicular lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) DE (Trial now transitioned) ES (Temporarily Halted) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001881-27 Sponsor Protocol Number: WO39210 Start Date*: 2017-03-01
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A phase III, multicenter, randomized, placebo-controlled, double-blind study of atezolizumab (anti-PD-L1 antibody) as adjuvant therapy in patients with renal cell carcinoma at high risk of developi...
    Medical condition: Patients at high risk of Renal Cell Carcinoma (RCC) recurrence after nephrectomy and select patients with metastatic RCC recurrence who have undergone complete metastasectomy
    Disease: Version SOC Term Classification Code Term Level
    11.0 100000004864 10038408 Renal cell carcinomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) NL (Completed) DE (Completed) GB (GB - no longer in EU/EEA) DK (Completed) CZ (Completed) BE (Completed) PL (Completed) ES (Completed) IE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 23:50:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA